Pardes Biosciences, Inc.

NasdaqGM:PRDS Stock Report

Market Cap: US$131.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Pardes Biosciences Management

Management criteria checks 1/4

Pardes Biosciences' CEO is Tom Wiggans, appointed in Mar 2022, has a tenure of 1.5 years. total yearly compensation is $5.26M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $107.99K. The average tenure of the management team and the board of directors is 2.7 years and 2.4 years respectively.

Key information

Tom Wiggans

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage9.9%
CEO tenure1.5yrs
CEO ownership0.08%
Management average tenure2.7yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

Jul 18
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

Jan 20
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Oct 01
We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19

Sep 13

Pardes Biosciences GAAP EPS of -$0.48

Aug 15

Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

Jun 14
Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform

Jan 21

CEO Compensation Analysis

How has Tom Wiggans's remuneration changed compared to Pardes Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$5mUS$521k

-US$97m

Compensation vs Market: Tom's total compensation ($USD5.26M) is above average for companies of similar size in the US market ($USD758.93K).

Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.


CEO

Tom Wiggans (71 yo)

1.5yrs

Tenure

US$5,255,958

Compensation

Mr. Thomas G. Wiggans, also known as Tom, serves as Independent Director at CymaBay Therapeutics, Inc. since April 2021. He serves as an Executive Chairman of Follica, Inc. since January 2021. He serves as...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Wiggans
CEO & Chairman of the Board1.5yrsUS$5.26m0.082%
$ 108.0k
Uri Lopatin
Founder & Directorno dataUS$3.52m9.35%
$ 12.3m
Heidi Henson
Chief Financial Officer2.7yrsUS$1.82m0.52%
$ 684.2k
Elizabeth Lacy
General Counsel & Corporate Secretary2.7yrsno data0.35%
$ 456.1k

2.7yrs

Average Tenure

56.5yo

Average Age

Experienced Management: PRDS's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Wiggans
CEO & Chairman of the Board1.5yrsUS$5.26m0.082%
$ 108.0k
Uri Lopatin
Founder & Director3.6yrsUS$3.52m9.35%
$ 12.3m
James Tananbaum
Director2.7yrsUS$110.69kno data
Mark Auerbach
Independent Director2.7yrsUS$170.69k0.12%
$ 152.0k
Michael Varney
Independent Director & Member of Scientific Advisory Board3.1yrsUS$153.69k0.12%
$ 152.0k
J. Lobell
Independent Director2.7yrsUS$163.19k2.25%
$ 2.9m
John Pottage
Independent Directorless than a yearUS$147.00k0%
$ 0
Laura Hamill
Independent Director2.2yrsUS$161.19k0%
$ 0
Laurie Smaldone Alsup
Lead Independent Directorless than a yearUS$146.94k0%
$ 0
Deborah Autor
Independent Director2.2yrsUS$153.69k0%
$ 0
Brad Jenkins
Member of Commercial Advisory Boardno datano datano data

2.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: PRDS's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.